Our Legal Mandate

What the law is, as this site understands it — and the publishing rules we follow because of it. Date-stamped November 7, 2026.

This is our charter, published so you can hold us to it. It states the law as we understand it from primary sources, and then the rules we impose on ourselves. It is not legal advice, and we are not your lawyer.

Part 1 — The law as we understand it (November 7, 2026)

1. No contested research peptide is FDA-approved. BPC-157, TB-500, MOTS-c, epitalon, semax, KPV and the rest of the creator catalog are unapproved drugs in the eyes of federal law, whatever their popularity.
2. Compounding runs on lists. A substance is lawfully compoundable under 503A when it reaches the 503A Bulks List (21 CFR 216.23) through PCAC review and rulemaking — or fits a separate lawful category, as sermorelin does. Being removed from Category 2 is not being placed on the Bulks List.
3. The October 30, 2026 HHS policy is enforcement discretion, not authorization. It is a draft, non-binding statement that HHS does not intend to pursue certain 503A compounding of six named peptides, in named forms, single-ingredient only, when ten conditions are met. It approves nothing, lists nothing, covers no blends, reaches no 503B facility, and blesses no research-chemical product.
4. “Research use only” is not a legal category for human use. FDA treats marketing, dosing guides, and human-use framing as evidence of intended use; RUO products sold for people are unapproved drugs, and the enforcement record (warning letters, seizures, the Kawa prosecution) proves the point.
5. States decide the rest. Prescribers and pharmacies answer to state boards; a federal enforcement posture does not preempt a stricter state. Federal win ≠ state permission.
6. Sport is a separate jurisdiction. WADA bans BPC-157 (S0) and most GH-axis peptides (S2) for tested athletes regardless of medical legality.

Part 2 — The rules we publish by

1. No dosing, protocol, or sourcing instructions. Ever. Not in articles, not in summaries, not in “what the creator said” framing. If a transcript passage crosses that line, we summarize around it or leave it out.
2. Every health claim is attributed to a named speaker or source, with the source’s nature stated (clinician, seller, critic, official document).
3. Sellers are labeled sellers — on their profile, on their videos, everywhere they appear. A discount code is an ad; we do not print them.
4. Inclusion is not endorsement. Covering a person, clinic, product, or company — in editorial or in a paid directory listing — is not a recommendation. Paid listings are disclosed as paid, always.
5. Directory standards. Listings are verified before publication (license primary-source check, discipline screen, pharmacy and ship-to-state license check), carry a paid-placement disclosure, and are pulled for the violations named in the listing agreement — including marketing blends as federally covered when they are not.
6. Right of reply. Any person or company named critically on this site may submit a reply; substantive replies are published or linked from the page in question.
7. Corrections. Factual errors are corrected visibly, with the correction dated. Policy and legal-status content is date-stamped and reviewed when the underlying record changes.
8. No medical advice. Nothing here tells you what to take. That conversation belongs to you and a licensed clinician who knows your history.

Publisher: Bowman Web Services LLC. Contact via the site’s contact page.